Clonal spread of levofloxacin-resistant Streptococcus pneumoniae invasive isolates in Madrid, Spain, 2007 to 2009

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2469-2471

  Rodríguez Avial, Iciar ^a   Ramos, Belén ^b   Ríos, Esther ^a   Cercenado, Emilia ^c,d   Ordobás, María ^b   Sanz, Juan Carlos ^b,e  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Grupo de Intervencion en Drogas de la Sociedad Espanola de Medicina Familiar Y Comunitaria   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; CLINDAMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; PENICILLIN G;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SEROTYPE; SPAIN; STREPTOCOCCUS PNEUMONIAE;

EID: 79955532602     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01380-10     Document Type: Article

References (20)

1. Ardanuy, C., et al. 2009. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin. Infect. Dis. 48:57-64.
2. Davidson, R., et al. 2002. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 346:747-750.
3. de Cueto, M., et al. 2008. Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation. J. Clin. Microbiol. 46:1558-1560.
4. de la Campa, A. G., et al. 2009. Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain. Emerg. Infect. Dis. 15:905-911.
5. de la Campa, A. G., et al. 2003. Genetic characterization of fluoroquinoloneresistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis. Antimicrob. Agents Chemother. 47:1419-1422.
6. de la Pedrosa, E. G., et al. 2008. Polyclonal population structure of Streptococcus pneumoniae isolates in Spain carrying mef and mef plus erm(B). Antimicrob. Agents Chemother. 52:1964-1969.
7. Eliopoulos, G. M. 2004. Quinolone resistance mechanisms in pneumococci. Clin. Infect. Dis. 38:S350-S356.
8. Enright, M. C., and B. G. Spratt. 1998. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 144:3049-3060.
9. Fenoll, A., et al. 2009. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J. Clin. Microbiol. 47:1012-1020.
10. Klugman, K. P. 2002. The successful clone: the vector of dissemination of resistance in Streptococcus pneumoniae. J. Antimicrob. Chemother. 50(Suppl. S2):1-5.
11. Lynch, J. P., III, and G. G. Zhanel. 2010. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr. Opin. Pulm. Med. 16:217-225.
12. Lynch, J. P., III, and G. G. Zhanel. 2009. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin. Respir. Crit. Care Med. 30:210-238.
13. Mahjoub-Messai, F., et al. 2009. Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal vaccination for French children. J. Clin. Microbiol. 47:837-840.
14. McEllistrem, M. C., J. E. Stout, and L. H. Harrison. 2000. Simplified protocol for pulsed-field gel electrophoresis analysis of Streptococcus pneumoniae. J. Clin. Microbiol. 38:351-353.
15. McGee, L., et al. 2001. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J. Clin. Microbiol. 39:2565-2571.
16. Moore, M. R., et al. 2008. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis. 197:1016-1027.
17. Morrissey, I., A. Colclough, and J. Northwood. 2007. TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from communityacquired respiratory tract infections in 2003 to fluoroquinolones and other agents. Int. J. Antimicrob. Agents 30:345-351.
18. Muñoz, R., and A. G. de la Campa. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257.
19. Muñoz-Almagro, C., et al. 2009. Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona. J. Infect. 59:75-82.
20. Pan, X. S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.